Thanks for that info, which is very interesting.
Recently I read through most of the threads on this rituximab sub-forum, specifically looking for people who had tried rituximab, to try to gauge the response rate.
Out of the 12 people I found on these forums who were treated with rituximab, only one person so far has responded (
@Rebecca2z, but she certainly responded very well — see
this thread). Though of this 12, there are two people who only recently started rituximab, so it is too early to tell. And there were also three people who stopped posting, so their status is unknown.
But we can say that out of the 7 people for which we have the full data, only 1 has responded to rituximab.
I understand that Rebecca's ME/CFS appeared as a result of chronic Epstein-Barr virus infection, some 30 years ago. So Rebecca's ME/CFS appears to have been EBV-triggered (remember that EBV chronically infects B cells).
It's conceivable that in Norway, there may have been an epidemic of ME/CFS caused by a particular pathogen, creating a specific subset of ME/CFS patients that respond well to rituximab.
There was in fact a
large outbreak of giardiasis in Bergen, Norway in 2004 (giardiasis = intestinal infection with the parasite Giardia lamblia), and
it was found that 5% of patients who came down with giardiasis in Bergen went on to develop ME/CFS. So Giardia lamblia appears to be a trigger of ME/CFS. (They also
found a 39% prevalence rate for IBS in these Bergen giardiasis cases, 6 years later).
Remember that it is at the Haukeland University Hospital in Bergen where Fluge and Mella are conducting their rituximab trials.
Thus it is quite conceivable that
Fluge and Mella may be treating many patients whose ME/CFS was originally triggered by Giardia lamblia, or patients for whom Giardia lamblia plays a significant role in their disease, because these patients caught Giardia lamblia during the 2004 outbreak in Bergen.
Now I read that Giardia lamblia is linked to autoimmune diseases, particularly with neurological autoimmune processes such as multiple sclerosis, ALS (Lou Gehrig’s disease), and Parkinson’s disease (ref:
here, but unsure of the validity of this source). So when Giardia lamblia triggers ME/CFS, this parasite may be precipitating an autoimmune-driven type of ME/CFS.
This may explain why rituximab works so well for ME/CFS patients in Bergen.